3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Completed
4
Recruiting
2
Not yet recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gynecologic
1
Breast
1
Conditions
Prostatic Neoplasms
220
Urinary Bladder Neoplasms
54
Carcinoma, Renal Cell
52
Neoplasms
27
Non-Muscle Invasive Bladder Neoplasms
26
Kidney Neoplasms
25
Breast Neoplasms
17
Carcinoma, Transitional Cell
16
Adenocarcinoma
15
Melanoma
11
Disease
11
Neoplasm Metastasis
10
Colorectal Neoplasms
10
Uterine Cervical Neoplasms
9
Endometrial Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Ovarian Neoplasms
7
Lung Neoplasms
7
Triple Negative Breast Neoplasms
6
Testicular Neoplasms
6
Recurrence
6
Clear-cell metastatic renal cell carcinoma
6
Urologic Neoplasms
5
Urinary Incontinence
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pancreatic Neoplasms
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Interventions
pembrolizumab
1
enfortumab vedotin
1
Single Person
1
Exercise
1
Acupuncture Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Peripheral Nervous System Diseases
×
Genitourinary
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled